Tom Keelin

Managing Partner

Tom, a founding partner of KR, has supervised portfolio management, asset strategy and valuation, or deal terms assessment and negotiations projects for more than 30 emerging growth life sciences companies. To support emerging-biotech decisions about when to partner and under what terms, he supervised a joint effort between KR and the Biotechnology Industry Organization (BIO) to develop, benchmark, and validate a way to estimate asset-specific deal terms based on the asset-specific economic characteristics and relative strength of negotiating position of the parties. In parallel, he invented, tested, and authored a patent application on an innovative R&D productivity simulation method which uniquely highlights improved portfolio management approaches that may more than double R&D productivity for some companies. Previously, he led business and product strategy efforts for many Global 1000 companies He also pioneered and helped them implement their adopted methods for asset valuation and portfolio management. He is a co-author of the Harvard Business Review article “How SmithKline Beecham Makes Better Resource Allocation Decisions” (Mar-Apr ‘98), founder of the Life Sciences practice within SDG and served as SDG’s Worldwide Managing Director and head of its strategy and strategy implementation consulting practices. Tom has testified before legislative or regulatory bodies in California, Illinois, Indiana, New York, Wisconsin and Ontario on issues of decision quality, investment risk analysis under uncertainty, prudence, usefulness and customer markets.

Tom is a founder and is on the Board of Directors of the Decision Education Foundation. He holds three degrees from Stanford University: BA in economics and MS and PhD in Engineering-Economic Systems.